CKLIFE SCIENCES (00775) Surges Over 8% Again as Company Showcases Tumor Growth Inhibition R&D Achievements, Vaccine Development Expected to Accelerate

Stock News

Yesterday

CKLIFE SCIENCES (00775) rose over 8% again, gaining 8.6% to HK$1.01 by the time of writing, with a turnover of HK$23.28 million. The company presented its tumor growth inhibition research achievements at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. Key highlights included significant progress in developing cancer vaccines targeting trophoblast cell surface antigen 2 (TROP2), preferentially expressed antigen in melanoma (PRAME), and programmed death-ligand 1 (PD-L1), demonstrating potential in suppressing tumor growth. Dr. To Kin Ming, Vice President and Scientific Director of CKLIFE SCIENCES, stated that the encouraging results of the company’s TROP2 and PRAME/PD-L1 cancer vaccine candidates are expected to accelerate the development of effective therapeutic cancer vaccines. The current goal is to advance these candidates to clinical trial stages.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1159446555"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159446555\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159446555?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159446555","market":"sg","top_or_hot":-1,"title":"CKLIFE SCIENCES (00775) Surges Over 8% Again as Company Showcases Tumor Growth Inhibition R&D Achievements, Vaccine Development Expected to Accelerate","media":"Stock News","content":"<p>CKLIFE SCIENCES (00775) rose over 8% again, gaining 8.6% to HK$1.01 by the time of writing, with a turnover of HK$23.28 million. The company presented its tumor growth inhibition research achievements at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. Key highlights included significant progress in developing cancer vaccines targeting trophoblast cell surface antigen 2 (TROP2), preferentially expressed antigen in melanoma (PRAME), and programmed death-ligand 1 (PD-L1), demonstrating potential in suppressing tumor growth. Dr. To Kin Ming, Vice President and Scientific Director of CKLIFE SCIENCES, stated that the encouraging results of the company’s TROP2 and PRAME/PD-L1 cancer vaccine candidates are expected to accelerate the development of effective therapeutic cancer vaccines. The current goal is to advance these candidates to clinical trial stages.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CKLIFE SCIENCES (00775) Surges Over 8% Again as Company Showcases Tumor Growth Inhibition R&D Achievements, Vaccine Development Expected to Accelerate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCKLIFE SCIENCES (00775) Surges Over 8% Again as Company Showcases Tumor Growth Inhibition R&D Achievements, Vaccine Development Expected to Accelerate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-13 14:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CKLIFE SCIENCES (00775) rose over 8% again, gaining 8.6% to HK$1.01 by the time of writing, with a turnover of HK$23.28 million. The company presented its tumor growth inhibition research achievements at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. Key highlights included significant progress in developing cancer vaccines targeting trophoblast cell surface antigen 2 (TROP2), preferentially expressed antigen in melanoma (PRAME), and programmed death-ligand 1 (PD-L1), demonstrating potential in suppressing tumor growth. Dr. To Kin Ming, Vice President and Scientific Director of CKLIFE SCIENCES, stated that the encouraging results of the company’s TROP2 and PRAME/PD-L1 cancer vaccine candidates are expected to accelerate the development of effective therapeutic cancer vaccines. The current goal is to advance these candidates to clinical trial stages.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1569","symbol_name":"长和系","start_time":0,"source_url":"","article_id":"1159446555","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159446555","pubTimestamp":1763015295,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CKLIFE SCIENCES (00775) rose over 8% again, gaining 8.6% to HK$1.01 by the time of writing, with a turnover of HK$23.28 million. The company presented its tumor growth inhibition research...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","BK1569":"长和系","BK1161":"生物科技","00775":"长江生命科技"},"translate_title":"CKLIFE SCIENCES(00775)再涨超8%公司展示肿瘤生长抑制研发成果疫苗研发有望加速","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"00775":1},"content_text":"CKLIFE SCIENCES (00775) rose over 8% again, gaining 8.6% to HK$1.01 by the time of writing, with a turnover of HK$23.28 million. The company presented its tumor growth inhibition research achievements at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. Key highlights included significant progress in developing cancer vaccines targeting trophoblast cell surface antigen 2 (TROP2), preferentially expressed antigen in melanoma (PRAME), and programmed death-ligand 1 (PD-L1), demonstrating potential in suppressing tumor growth. Dr. To Kin Ming, Vice President and Scientific Director of CKLIFE SCIENCES, stated that the encouraging results of the company’s TROP2 and PRAME/PD-L1 cancer vaccine candidates are expected to accelerate the development of effective therapeutic cancer vaccines. The current goal is to advance these candidates to clinical trial stages.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}